The rubbing of the hands is one of the clinical manifestations of Parkinson’s syndrome. It is a degenerative disease of the substantia nigra and substantia nigra striata pathways that occurs in adults over middle age. 10% of patients have a family history; some patients can have similar manifestations due to encephalitis, cerebral atherosclerosis, and traumatic brain injury. The cause of Parkinson’s disease is not well understood. It is now recognized that the cause of Parkinson’s disease is degenerative changes of nerve cells, with the main lesions in the substantia nigra and striatum. The gradual decrease in the number of nigrostriatal cells and the gradual loss of their function leads to a decrease in a substance called dopamine, which causes the above symptoms. According to the results of animal experiments and epidemiology, Parkinson’s disease is also related to genetics. 1, magnetic resonance Magnetic resonance can be used to differentially diagnose diseases such as Parkinson’s disease by showing some organic lesions. Magnetization transfer imaging can detect melanin reduction in Parkinson’s disease patients and can distinguish morphological changes in different areas of the brain caused by different degrees of Parkinson’s disease lesions. Magnetic resonance spectroscopy can be used for neurobiochemical testing starting from Parkinson’s disease brain metabolism. 2.Positron emission computed tomography imaging Currently, positron emission computed tomography imaging is used in the field of Parkinson’s disease diagnosis, including dopaminergic system imaging and non-dopaminergic system imaging, with various types of ligands, including dopamine transporter imaging, type II vesicle monoamine transporter imaging and dopamine D2 receptor imaging; non-dopaminergic system imaging includes glucose metabolism imaging, micro The non-dopaminergic system imaging includes glucose metabolism imaging, small glial cell imaging, etc. Transcranial color Doppler ultrasound Transcranial color Doppler ultrasound is a new discovery in the diagnosis of Parkinson’s disease in recent years. The value of transcranial ultrasound as a screening biomarker has been confirmed by numerous reproducible studies, but the limitation of its application is that the acoustic attenuation of the skull affects the display of the acoustic window, thus affecting the detection rate.